Fardis Maria 4

What Happened Fardis Maria, a director of CRISPR Therapeutics AG (CRSP), received a grant of derivative awards (options) covering 13,000 shares on June 5, 2026. The reported acquisition price for the grant is $0.00 (no cash paid at grant). The footnote states these options will vest and become exercisable in 12 equal monthly installments, with the first installment vesting June 30, 2026 and the final installment vesting on the earlier of the one‑year anniversary of the grant or the 2027 Annual Meeting. The filing does not disclose an exercise price in the provided excerpt.

Key Details

• Transaction date: 2026-06-05 (grant of award, reporting code A)
• Report filed: 2026-06-09 (appears timely)
• Shares/units granted: 13,000 (derivative/options)
• Price paid at grant: $0.00 (grant; no cash outlay reported)
• Vesting: 12 equal monthly installments; first vests 6/30/2026; last vests earlier of one‑year anniversary or 2027 Annual Meeting (see footnote)
• Exercise price and post‑transaction beneficial ownership: not specified in the provided filing excerpt
• No sale or exercise occurred — this is a compensation grant to a director

Context This is a director compensation award (an option grant) rather than an open‑market purchase or sale. Options must be exercised to create common shares; the grant itself does not involve immediate proceeds or sales. Director option grants are common as compensation and do not, by themselves, indicate a buying/selling signal. The filing date suggests the report was submitted within the SEC’s required timeframe.